Skip to Content

Davanat Approval Status

Davanat is a polysaccharide polymer comprised of mannnose and galactose in development for the targeted delivery of drugs used in the treatment of cancer.

Development Status and FDA Approval Process for Davanat

Sep 15, 2008Pro-Pharmaceuticals Submits Data to FDA for Davanat NDA to Treat Advanced Colorectal Cancer
May 20, 2008Pro-Pharmaceuticals Announces Submission of Drug Master File for Davanat to FDA
May  1, 2008Pro-Pharmaceuticals Updates NDA Filing for Davanat
Dec 19, 2007Pro-Pharmaceuticals Selects SAFC, a Division of Sigma-Aldrich, to Submit a Drug Master File
Jun 11, 2007Pro-Pharmaceuticals Submits Data to Begin a 505 (b)(2) Filing with the FDA for a New Formulation of Irinotecan to be Co-administered with Davanat as a Functional Excipient
Apr 11, 2007Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for Davanat/ 5-FU
Feb  7, 2007Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of Davanat with 5-FU in Cancer Patients

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.